| pubmed-article:17725413 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17725413 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:17725413 | lifeskim:mentions | umls-concept:C0035820 | lld:lifeskim |
| pubmed-article:17725413 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:17725413 | lifeskim:mentions | umls-concept:C0035525 | lld:lifeskim |
| pubmed-article:17725413 | lifeskim:mentions | umls-concept:C0524910 | lld:lifeskim |
| pubmed-article:17725413 | lifeskim:mentions | umls-concept:C0444917 | lld:lifeskim |
| pubmed-article:17725413 | lifeskim:mentions | umls-concept:C0231449 | lld:lifeskim |
| pubmed-article:17725413 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:17725413 | pubmed:dateCreated | 2007-8-29 | lld:pubmed |
| pubmed-article:17725413 | pubmed:abstractText | The response to pegylated interferon (pegIFN) plus ribavirin (RBV) as treatment of chronic hepatitis C virus (HCV) infection is lower in HIV-coinfected than in HCV-monoinfected patients and could be due to suboptimal RBV dosing and/or insufficient duration of therapy in prior trials. In a prospective, multicenter, open, comparative trial, HCV/HIV-coinfected patients received pegIFN plus weight-based RBV for 48 or 72 weeks (HCV genotypes 1 and 4) and 24 or 48 weeks (HCV genotypes 2 and 3). Use of didanosine was not allowed. Out of 389 patients included in the trial, 61% were infected by HCV-1/4 and 67% had serum HCV-RNA >500,000 IU/ml. Sustained virological response (SVR) was achieved by 49.6%, significantly higher in HCV-2/3 than HCV-1/4 (72.4% vs. 35%; p < 0.0001). A high drop-out rate in the longer treatment arms precluded obtaining definitive conclusions about the efficacy of prolonging therapy. Premature treatment discontinuations due to serious adverse events occurred in 8.2%. Infection with HCV-2/3, lower baseline HCV-RNA, and negative HCV-RNA at week 12 were all independent predictors of SVR in the multivariate analysis. The use of RBV 1000-1200 mg/day plus pegIFN is relatively safe and provides SVR in nearly half of coinfected patients, twice as high in HCV-2/3 than HCV-1/4. | lld:pubmed |
| pubmed-article:17725413 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17725413 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17725413 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17725413 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17725413 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17725413 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17725413 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17725413 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17725413 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17725413 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17725413 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17725413 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17725413 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17725413 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:17725413 | pubmed:issn | 0889-2229 | lld:pubmed |
| pubmed-article:17725413 | pubmed:author | pubmed-author:Aguirrebengoa... | lld:pubmed |
| pubmed-article:17725413 | pubmed:author | pubmed-author:BarreiroPablo... | lld:pubmed |
| pubmed-article:17725413 | pubmed:author | pubmed-author:SorianoVincen... | lld:pubmed |
| pubmed-article:17725413 | pubmed:author | pubmed-author:NúñezMarinaM | lld:pubmed |
| pubmed-article:17725413 | pubmed:author | pubmed-author:MirallesCelia... | lld:pubmed |
| pubmed-article:17725413 | pubmed:author | pubmed-author:García-Samani... | lld:pubmed |
| pubmed-article:17725413 | pubmed:author | pubmed-author:RomeroMiriamM | lld:pubmed |
| pubmed-article:17725413 | pubmed:author | pubmed-author:OcampoAntonio... | lld:pubmed |
| pubmed-article:17725413 | pubmed:author | pubmed-author:CervantesManu... | lld:pubmed |
| pubmed-article:17725413 | pubmed:author | pubmed-author:AsensiVictorV | lld:pubmed |
| pubmed-article:17725413 | pubmed:author | pubmed-author:LosadaElenaE | lld:pubmed |
| pubmed-article:17725413 | pubmed:author | pubmed-author:GalindoMaría... | lld:pubmed |
| pubmed-article:17725413 | pubmed:author | pubmed-author:ArazoPiedadP | lld:pubmed |
| pubmed-article:17725413 | pubmed:author | pubmed-author:BerdúnMiguel... | lld:pubmed |
| pubmed-article:17725413 | pubmed:author | pubmed-author:SolaJulioJ | lld:pubmed |
| pubmed-article:17725413 | pubmed:author | pubmed-author:San... | lld:pubmed |
| pubmed-article:17725413 | pubmed:author | pubmed-author:PRESCO... | lld:pubmed |
| pubmed-article:17725413 | pubmed:author | pubmed-author:de Los... | lld:pubmed |
| pubmed-article:17725413 | pubmed:author | pubmed-author:EcheverríaSan... | lld:pubmed |
| pubmed-article:17725413 | pubmed:author | pubmed-author:Hernandez-Bur... | lld:pubmed |
| pubmed-article:17725413 | pubmed:author | pubmed-author:GuardiolaJose... | lld:pubmed |
| pubmed-article:17725413 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17725413 | pubmed:volume | 23 | lld:pubmed |
| pubmed-article:17725413 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17725413 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17725413 | pubmed:pagination | 972-82 | lld:pubmed |
| pubmed-article:17725413 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:17725413 | pubmed:meshHeading | pubmed-meshheading:17725413... | lld:pubmed |
| pubmed-article:17725413 | pubmed:meshHeading | pubmed-meshheading:17725413... | lld:pubmed |
| pubmed-article:17725413 | pubmed:meshHeading | pubmed-meshheading:17725413... | lld:pubmed |
| pubmed-article:17725413 | pubmed:meshHeading | pubmed-meshheading:17725413... | lld:pubmed |
| pubmed-article:17725413 | pubmed:meshHeading | pubmed-meshheading:17725413... | lld:pubmed |
| pubmed-article:17725413 | pubmed:meshHeading | pubmed-meshheading:17725413... | lld:pubmed |
| pubmed-article:17725413 | pubmed:meshHeading | pubmed-meshheading:17725413... | lld:pubmed |
| pubmed-article:17725413 | pubmed:meshHeading | pubmed-meshheading:17725413... | lld:pubmed |
| pubmed-article:17725413 | pubmed:meshHeading | pubmed-meshheading:17725413... | lld:pubmed |
| pubmed-article:17725413 | pubmed:meshHeading | pubmed-meshheading:17725413... | lld:pubmed |
| pubmed-article:17725413 | pubmed:meshHeading | pubmed-meshheading:17725413... | lld:pubmed |
| pubmed-article:17725413 | pubmed:meshHeading | pubmed-meshheading:17725413... | lld:pubmed |
| pubmed-article:17725413 | pubmed:meshHeading | pubmed-meshheading:17725413... | lld:pubmed |
| pubmed-article:17725413 | pubmed:meshHeading | pubmed-meshheading:17725413... | lld:pubmed |
| pubmed-article:17725413 | pubmed:meshHeading | pubmed-meshheading:17725413... | lld:pubmed |
| pubmed-article:17725413 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17725413 | pubmed:articleTitle | Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. | lld:pubmed |
| pubmed-article:17725413 | pubmed:affiliation | Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain. | lld:pubmed |
| pubmed-article:17725413 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17725413 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:17725413 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:17725413 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17725413 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17725413 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17725413 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17725413 | lld:pubmed |
